Arcadia Biosciences (RKDA) AI Stock Analysis

• Market Cap: $6.81M
• Dividend Yield: N/A
• Average Volume (3M): 13.59K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.53
• Revenue Growth: -2.81%
• EPS Growth: 72.03%
• Country: US
• Employees: 9
• Sector: Healthcare
• Sector Strength: 53
• Industry: Agricultural Inputs
• EPS (TTM): 1.90
• Shares Outstanding: 1,367,040
• 10 Day Avg. Volume: 13,244
• 30 Day Avg. Volume: 13,592
• PEG Ratio: 0.03
• Price to Book (P/B): 0.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.46
• Enterprise Value/Market Cap: -1.78
• Enterprise Value/Revenue: -0.57
• Enterprise Value/Gross Profit: -5.82
• Enterprise Value/Ebitda: 0.35
• 1Y Price Target: $12.00
• Price Target Upside: 140.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: $5.00 ▲(0.40%Upside)

Arcadia Biosciences' score reflects strong technical momentum and positive earnings call insights, counterbalanced by financial performance challenges, a negative valuation, and recent corporate event risks.

Positive Factors

Financial Performance

Q4’24 results were ahead of expectations behind Zola coconut water growth of 124% via an 86% distribution increase.

Market Expansion

Zola’s 80% distribution expansion in 2024 to approximately 3,000 stores is providing considerable visibility for year-over-year growth.

Negative Factors

Portfolio Monetization

Management noted they continue to seek further monetization of legacy ag biotech IP and expect a series of transactions to unwind this portfolio.

Valuation Concern

Arcadia's current valuation levels are considered materially depressed relative to a post-merger fair value, making it an attractive option for special situation and/or merger arbitrage investors.

Arcadia Biosciences Business Overview & Revenue Model

Company Description

Arcadia Biosciences (RKDA) is a publicly traded agricultural biotechnology company focused on developing and commercializing high-value crop improvements to enhance productivity and quality. The company operates in the agriculture sector, specializing in the genetic modification of crops to improve their nutritional value, stress tolerance, and yield. Arcadia's core products and services include proprietary seeds and traits that enhance the nutritional quality and environmental sustainability of crops such as wheat, soybean, and hemp.

How the Company Makes Money

Arcadia Biosciences generates revenue primarily through the sale of its proprietary seeds and agricultural traits. The company licenses its technology to other agricultural firms, enabling them to produce crops with enhanced features such as improved nutritional content, resistance to pests and disease, and better adaptability to environmental stresses. Arcadia also forms strategic partnerships and collaborations with other agribusinesses and research institutions to co-develop and commercialize new technologies. Additionally, the company may engage in the sale of agricultural products derived from its proprietary crops. Revenue streams are further supported by government grants and research funding aimed at advancing agricultural innovation.

Arcadia Biosciences Financial Statement Overview

Summary

Arcadia Biosciences faces financial challenges with declining revenue and consistent net losses, but maintains a solid equity position and low debt.

Income Statement

Arcadia Biosciences has faced challenges in maintaining revenue growth and profitability. The revenue decreased slightly from $5.33 million in 2023 to $5.045 million in 2024, indicating a revenue decline of approximately 5.35%. The gross profit margin improved slightly, but the company remains unprofitable with a negative net income for the year ending 2024. EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The balance sheet shows a moderate level of financial stability with a debt-to-equity ratio of 0.025, indicating low leverage. However, the return on equity remains negative due to consistent net losses. The equity ratio is 46%, indicating a solid equity position relative to total assets.

Cash Flow

Arcadia Biosciences experienced substantial free cash flow challenges, with negative free cash flow growth. Operating cash flow to net income ratio is negative, reflecting cash flow difficulties. However, cash flow from investing activities was positive, indicating some level of investment recovery.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
5.26M	5.04M	5.33M	9.96M	6.78M	8.03M
	Gross Profit
2.08M	2.08M	2.03M	154.00K	-1.93M	2.83M
	EBIT
-1.53M	-3.65M	-13.87M	-19.40M	-35.53M	-21.59M
	EBITDA
-5.47M	-7.50M	-13.58M	-13.65M	-23.27M	-5.44M
	Net Income Common Stockholders
-2.02M	-7.04M	-13.98M	-15.61M	-16.13M	-6.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.16M	4.24M	11.64M	20.64M	28.68M	25.67M
	Total Assets
12.99M	13.52M	19.70M	28.92M	43.92M	47.35M
	Total Debt
21.00K	155.00K	1.01M	2.02M	3.29M	9.35M
	Net Debt
-3.14M	-4.09M	-5.51M	-18.63M	-25.39M	-4.69M
	Total Liabilities
4.08M	7.29M	7.00M	8.02M	12.72M	18.80M
	Stockholders Equity
8.90M	6.22M	12.84M	21.03M	31.09M	27.73M
Cash Flow		Free Cash Flow
-8.01M	-9.64M	-15.30M	-14.05M	-26.88M	-32.55M
	Operating Cash Flow
-8.01M	-9.63M	-15.29M	-13.98M	-25.87M	-30.22M
	Investing Cash Flow
7.84M	7.34M	-4.34M	1.42M	16.61M	17.28M
	Financing Cash Flow
9.00K	9.00K	5.51M	4.52M	21.90M	20.56M

Arcadia Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Positive. The current price of 4.98 is above the 20-day moving average (MA) of 4.69, above the 50-day MA of 3.97, and above the 200-day MA of 3.98, indicating a bullish trend. The MACD of 0.28 indicates Positive momentum. The RSI at 66.91 is Neutral, neither overbought nor oversold. The STOCH value of 58.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RKDA.

Arcadia Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RKDA	58 Neutral	$6.81M	―	-7.89%	―	-2.81%	72.03%
Sector *	54 Neutral	$5.34B	3.36	-45.10%	3.39%	16.81%	-0.03%
XYLO	48 Neutral	$3.94M	―	-28.99%	―	-67.77%	66.19%
EVOK	46 Neutral	$4.40M	―	-108.77%	―	97.84%	82.99%
SONN	45 Neutral	$3.70M	―	-714.96%	―	978.39%	69.65%
TTNP	34 Underperform	$3.88M	―	-105.70%	―	-100.00%	28.48%
GLTO	29 Underperform	$4.38M	―	-91.32%	―	―	48.81%

Arcadia Biosciences Corporate Events

Arcadia Biosciences Faces Payment Default from Above Food

On May 14, 2024, Arcadia Biosciences and its subsidiary sold certain assets of its GoodWheat business to Above Food Corp. and transferred $2 million in cash as part of an Asset Purchase Agreement. In return, Arcadia received a promissory note for $6 million, with payments scheduled over three years. However, as of May 14, 2025, Above Food Corp. failed to make the first payment, leading to a potential default situation. Arcadia is considering actions to enforce its rights under the agreement. Additionally, Arcadia is involved in a proposed all-stock transaction with Roosevelt Resources, which involves the exchange of shares and is subject to regulatory approval.

The most recent analyst rating on (RKDA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Arcadia Biosciences stock, see the RKDA Stock Forecast page.